Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Lilly

Pharmaceutical sales up 8% in the quarter driven by Trulicity

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly
2Q Revenues: $5.8 billion (+8%)
2Q Earnings: $1.0 billion (+35%)
YTD Revenues: $11.1 billion (+8%)
YTD Earnings: $2.2 billion (-24%)
Comments: The increase in worldwide volume was due to 8% pharmaceutical growth driven by Trulicity, with sales up 139% to $480.2 million and other new products, including Taltz ($139 million, +618%), Jardiance ($103.2 million, +157%), and Cyramza ($186.3 million, +27%). These increases were partially offset by decreased volumes for Cialis, flat at $627.3 million, Zyprexa, down 33% to $140.8 million, Alimta, down 12% to $532.9 million, and Strattera, down 17% to $186.6 million. Revenue in the U.S. increased 15% to $3.3 billion, due to higher realized prices for several pharmaceutical products, primarily driven by Cialis and Forteo, and increased volume for new products, driven by Trulicity, Taltz, Basaglar, Jardiance and Lartruvo. Revenue outside the U.S. decreased 1% to $2.5 billion, due to the loss of exclusivity of Zyprexa in Japan and Cymbalta in Canada and Europe, as well as increased competition, lower realized prices and loss of exclusivity for Alimta in several countries.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters